A functional polymorphism in the promoter of MiR-143/145 is associated with the risk of cervical squamous cell carcinoma in Chinese Women: A case-control study

Medicine (United States)

Volumn 94, Issue 31, 2015, Pages

  Liang, Yundan ^a,b   Sun, Ruifen ^a,b,c   Li, Lijuan ^a,b   Yuan, Fang ^a,b   Liang, Weibo ^d   Wang, Li ^a   Nie, Xinwen ^a,b   Chen, Peng ^a   Zhang, Lin ^a,b   Gao, Linbo ^a,b   Efird, Jimmy ^d  

^a SICHUAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c YUNNAN UNIVERSITY   (China)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MICRORNA 143; MICRORNA 145; KRAS PROTEIN, HUMAN; MICRORNA; MIRN143 MICRORNA, HUMAN; MIRN145 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC MODEL; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIFACTOR DIMENSIONALITY REDUCTION; PARITY; PREGNANCY; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSIENT TRANSFECTION; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; FEMALE; GENOTYPE; HUMANS; MICRORNAS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84942411114     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001289     Document Type: Article

References (46)

1. Malleter M, Jacquot C, Moreau D, et al. A novel large regulator RNA, B2, partially overlaps the HEF1/NEDD9/Cas-L gene. Int J Mol Med. 2010; 25: 897-903.
2. Kent A. HPV vaccination and testing. Rev Obstet Gynecol. 2010; 3: 33-34.
3. Herrington CS Do HPV-negative cervical carcinomas exist? - revisited. J Pathol. 1999; 189: 1-3.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papilloma-virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
5. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890-907.
6. Dunne EF, Park IU. HPV and HPV-associated diseases. Infect Dis Clin N Am. 2013; 27: 765-778.
7. Appleby P, Beral V, et al, International Collaboration of Epidemiological Studies of Cervical C. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006; 118: 1481-1495.
8. International Collaboration of Epidemiological Studies of Cervical C. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006; 119: 1108-1124.
9. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370: 1609-1621.
10. Gao LB, Pan XM, Li LJ, et al. Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS ONE. 2011; 6: e20157.
11. Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
12. Bartel DP MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
13. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS. 2007; 115: 1090-1106.
14. Nieters A, Yuan JM, Sun CL, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 2005; 103: 740-748.
15. Voorhoeve PM, Le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124: 1169-1181.
16. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 2008; 3: e2557.
17. Chen Y, Ma C, Zhang W, et al. Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer. Diagn Pathol. 2014; 9: 88.
18. Lui WO, Pourmand N, Patterson BK, et al. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007; 67: 6031-6043.
19. Liu L, Yu X, Guo X, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012; 5: 753-760.
20. Huang L, Lin JX, Yu YH, et al. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS ONE. 2012; 7: e33762.
21. Deftereos G, Corrie SR, Feng Q, et al. Expression of miR-21 and miR-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS ONE. 2011; 6: e28423.
22. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28: 1385-1392.
23. Pekow J, Meckel K, Dougherty U, et al. Tumor suppressors miRNA-143 and miR-145 and predicted target proteins API5, ERK5, KRAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol. 2015; 308: G179-G187.
24. Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010; 24: 2754-2759.
25. Kent OA, McCall MN, Cornish TC, et al. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014; 42: 7528-7538.
26. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. 2013; 32: 2576-2585.
27. Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2006; 100: 596-600.
28. Kang S, Kim HS, Seo SS, et al. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol. 2007; 105: 662-666.
29. Wright AA, Howitt BE, Myers AP, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013; 119: 3776-3783.
30. Luo X, Yang W, Ye DQ, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011; 7: e1002128.
31. Li L, Pan X, Li Z, et al. Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol. 2013; 74: 993-997.
32. Kim M, Chen X, Chin LJ, et al. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle. 2014; 13: 1030-1040.
33. Pan XM, Sun RF, Li ZH, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014; 35: 831-835.
34. Pan XM, Jia J, Guo XM, et al. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma. Fam Cancer. 2014; 13: 93-97.
35. Li ZH, Pan XM, Han BW, et al. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013; 34: 3159-3163.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25: 402-408.
37. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003; 19: 376-382.
38. Moore JH, Andrews PC. Epistasis analysis using multifactor dimensionality reduction. Method Mol Biol. 2015; 1253: 301-314.
39. Mouron SA, Abba MC, Guerci A, et al. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions. Mut Res. 2000; 469: 127-134.
40. Stenzel A, Semczuk A, Rozynskal K, et al. Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases. Pathol Res Pract. 2001; 197: 597-603.
41. Wegman P, Ahlin C, Sorbe B. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. Int J Gynecol Cancer. 2011; 21: 86-91.
42. Wang WY, Chien YC, Wong YK, et al. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck. 2012; 34: 663-666.
43. Jin H, Liang Y, Wang X, et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol. 2014; 31: 221.
44. Atighechi S, Baghdadabad MRA, Mirvakili SA, et al. Human papilloma virus and nasopharyngeal carcinoma: pathology, prognosis, recurrence and mortality of the disease. Exp Oncol. 2014; 36: 215-216.
45. Robinson M, Suh YE, Paleri V, et al. Oncogenic human papilloma-virus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect Agents Cancer. 2013; 8: 30.
46. Mekenkamp LJ, Tol J, Dijkstra JR, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012; 12: 292.